ORBIMED ADVISORS LLC 13D and 13G filings for Janux Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-08-09 4:09 pm Sale | 2024-07-31 | 13D | Janux Therapeutics, Inc. JANX | ORBIMED ADVISORS LLC | 1,965,266 3.800% | -684,198 (-25.82%) | Filing |
| 2021-12-17 5:08 pm Purchase | 2021-12-16 | 13D | Janux Therapeutics, Inc. JANX | ORBIMED ADVISORS LLC | 2,649,464 6.400% | 2,649,464 (New Position) | Filing |